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Zusammenfassung
Die Wachstumsfaktoren vascular endothelial growth factor
(VEGF)-A, -C und -D sind Mitglieder der proangiogenen
VEGF-Glycoprotein-Familie. VEGF-A ist der wichtigste An-
giogenesefaktor unter physiologischen und pathologischen
Bedingungen, während VEGF-C und VEGF-D an der Lymph-
angiogenese, der Entwicklung und dem Wachstum von
Lymphgefäßen beteiligt sind. Lokale Tumorprogression, lym-
phatische Metastasierung und hämatogene Tumoraussaat
sind wichtige Prognosefaktoren des Ösophaguskarzinoms
(EC), einer der tödlichsten Tumorerkrankungen weltweit. In
der Literatur finden sich sichere Hinweise für den Einfluss
der VEGF-Expression auf die Tumorangiogenese, Tumorpro-
gression und lymphatische Metastasierung beim Plattenepi-
thelkarzinom des Ösophagus (SCC), etliche Autoren konnten
hier einen prognostischen Wert von VEGF Messungen nach-
weisen. Das Adenokarzinom des Ösophagus (AC) zeigt
schon in frühen Entwicklungsstadien ausgeprägte Eigen-
schaften der Tumorangiogenese, insbesondere bei Präkan-
zerosen wie der Barrett-Dysplasie. Ein prognostischer Wert
der VEGF-Expression beim Adenokarzinom des Ösophagus
wurde jedoch bisher nicht nachgewiesen. VEGF-C und -D
konnten beim SCC und dysplastischen Läsionen aber nicht
in normaler Ösophagusmukosa nachgewiesen werden. Ein
Einfluss von VEGF-C Expression auf Lymphgefäßinvasion,
lymphatische Metastasierung und fortgeschrittene Tumor-
stadien ösophagealer Plattenepithel- und Adenokarzinome
ist anzunehmen. Die therapeutische Hemmung der VEGF
Signaltransduktion könnte eine viel versprechende antian-
giogene Zusatztherapie des Ösophaguskarzinoms darstellen,
wobei konkrete klinische Daten bisher noch ausstehen. 
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Abstract
Vascular endothelial growth factors (VEGF)-A, -C and -D are
members of the proangiogenic VEGF family of glycopro-
teins. VEGF-A is known to be the most important angiogenic
factor under physiological and pathological conditions,
while VEGF-C and VEGF-D are implicated in the develop-
ment and sprouting of lymphatic vessels, so called lym-
phangiogenesis. Local tumor progression, lymph node
metastases and hematogenous tumor spread are important
prognostic factors for esophageal carcinoma (EC), one of
the most lethal malignancies throughout the world. We
found solid evidence in the literature that VEGF expression
contributes to tumor angiogenesis, tumor progression and
lymph node metastasis in esophageal squamous cell carci-
noma (SCC), and many authors could show a prognostic
value for VEGF-assessment. In adenocarcinoma (AC) of the
esophagus angiogenic properties are acquired in early
stages, particularly in precancerous lesions like Barrett’s
dysplasia. However, VEGF expression fails to give prognos-
tic information in AC of the esophagus. VEGF-C and -D were
detected in SCC and dysplastic lesions, but not in normal
mucosa of the esophagus. VEGF-C expression might be as-
sociated with lymphatic tumor invasion, lymph node metas-
tases and advanced disease in esophageal SCC and AC.
Therapeutic interference with VEGF signaling may prove to
be a promising way of anti-angiogenic co-treatment in
esophageal carcinoma. However, concrete clinical data are
still pending. 
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Background
Its now firmly established that the growth of new blood ves-
sels – angiogenesis – is critical to both the growth and metasta-
sis of solid tumors. The founding member VEGF-A (formerly
known as VEGF) represents the best-studied element of the
pro-angiogenic vascular endothelial growth factor family and
plays an outstanding role in angiogenesis, growth and
hematogenous spread of solid tumors (reviewed by Hicklin
and Ellis [1]). Binding of VEGF-A to its receptors (VEGFR-1
and VEGFR-2) initiates an intracellular signaling pathway
which results in stromal degeneration by proteolytic enzymes
[2], induces endothelial sprouting through proliferation and
migration of endothelial cells [3] and enhances vascular per-
meability for proteins, cells and plasma [1, 4]. VEGF-A pro-
tects endothelial cells from apoptosis and contributes to the
maintenance of the vascular system [5]. VEGF-C and -D are
relatively young members of the VEGF family, which are
structurally closely related to each other and share approxi-
mately 30% identity with VEGF-A. VEGF-C and VEGF-D
but not VEGF-A bind specifically to VEGFR-3 (flt-4). Its ex-
pression becomes restricted mainly to the lymphatic endothe-
lium of adult tissues. VEGFR-3 activation induces lymphatic
vessel growth – lymphangiogenesis – but has very little effect
on blood capillaries [6–8]. In contrast to its counterpart angio-
genesis, the mechanisms of lymphangiogenesis are far less well
understood and the presence or absence of functional intratu-
moral but not only peritumoral lymphatics remains controver-
sial [9–11]. However, in human malignancies tumor associated
lymphatics are well known key components of metastatic
spread. Ingrowths of tumor cells into peritumoral lymphatics
and migration via lymphatics are the most common pathways
of initial tumor dissemination.
Patients with esophageal carcinoma (EC) generally have a
worse prognosis than those with other types of gastrointestinal
tumors [12]. The pathological pN (node) status is the most
powerful predictor of outcome in squamous cell carcinoma
(SCC) of the esophagus [13–15]. Overall survival is poor, with
5-year survival rates of only 10–20%, whereas rates of up to
60% have been reported for node negative groups. The influ-
ence of tumor angiogenesis and pro-angiogenic molecules
such as vascular endothelial growth factors on progression and
recurrence of EC has been debated over the last years. The
following paragraphs will review the prognostic significance
of VEGF-A, -C and -D expression, in esophageal SCC, AC
(adenocarcinoma) and Barrett’s dysplasia, their predictive
value for treatment response to surgical, radiation- or
chemotherapy and new anti-VEGF strategies. 
Adenocarcinoma of the Esophagus and VEGF-A
Once gastro-esophageal reflux disease (GERD) has led to the
onset of metaplastic mucosa, metaplasia of the lower esopha-
gus appears to never totally regress [16]. Therefore, Barrett’s
metaplasia is one of the most common precancerous lesions in
the western world. In animal experiments Baatar et al. [17]
could show a potential role of VEGF-A expression in
esophageal ulcer healing and Auvinen et al. [18] could proove
that human Barrett’s esophagus is strongly neovascularized
and not simply eroded. Immunohistochemistry of surgically
resected tissue specimens revealed that the ‘salmon-red’ color
of Barrett’s mucosa was due to incipient angiogenesis, origi-
nating from the pre-existing vascular network in the lamina
propria [18]. Lord et al. demonstrated that VEGF-A mRNA
and protein expression in esophageal adenocarcinoma was
significantly increased compared with Barrett’s metaplasia,
dysplasia and normal mucosa [19]. In Barrett’s metaplasia
they found the strongest VEGF-A expression in mucin con-
taining goblet cells and microvessel density (MVD) was gen-
erally higher in AC compared with pre-neoplastic lesions.
Correspondingly, Couvelard et al. found VEGF-A protein ex-
pression in metaplastic and neoplastic epithelium, which cor-
related significantly with vascularization [20]. The authors re-
port stepwise increases in microvessel counts in high-grade
dysplasia, intra-mucosal carcinoma and superficial carcinoma
(pT1), but microvessel counts were reduced in infiltrative car-
cinoma and failed to provide prognostic information. Möbius
et al. could demonstrate continuously increasing VEGF-A ex-
pression values in metaplasia, high-grade dysplasia, microin-
vasive carcinoma, and advanced carcinoma and conclude that
an angiogenic switch occurs as an early event in the metapla-
sia-dysplasia-carcinoma sequence of Barrett’s carcinoma [21].
However, VEGF-A did not correlate with patient survival or
other clinicopathological data [22]. In conclusion, angiogenic
properties are acquired early, particularly in pre-cancerous le-
sions, representing a critical step in the development of Bar-
rett’s carcinoma [23]. These findings could provide one possi-
ble explanation for the early onset of local spread and fre-
quent recurrence of esophageal carcinoma. However, VEGF
expression patterns apparently fail to give prognostic informa-
tion in invasive adenocarcinoma of the esophagus.
Squamous Cell Carcinoma of the Esophagus and VEGF-A
While only a few studies have been published regarding
VEGF-A expression in Barrett’s dysplasia and AC, an in-
creasing number of papers deal with VEGF-A expression in
SCC of the esophagus. The main results from those studies are
summarized in table 1. All of them revealed VEGF-A expres-
sion of SCC to some degree (24–93%) [24–46]. Endoscopical-
ly obtained biopsies yielded similar results [37, 40]. VEGF-A
gene expression in esophageal SCC tissue could be demon-
strated using RT-PCR for VEGF-A mRNA, and circulating
serum-VEGF-A was detected by ELISA [29, 31, 35, 36, 38,
39, 44]. Several authors additionally assessed vascularization
and could show correlations between VEGF-A protein ex-
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Reference Patients, VEGF-A Correlation of VEGF-A with Prognostic value of VEGF-A
n positive 
tumors, % pathology MVD, p univariate, p multivariate, p
Ahn et al., 2002 [30] 81 51 – – –
Du et al., 2003 [43] 59 81 N+, G <0.05
Hironaka et al., 2002 [37] 73 49 0.94
Imdahl et al., 2002 [40] 21* + 0.021 –
Inoue et al., 1997 [36] 75 47 dI, M+, V+, G 0.0002 0.016 0.008
Kimura et al., 2004 [46] 82 62 0.002 0.002
Kitadai et al., 1998 [34] 119 60 dI, S, L+, V+ <0.01 0.201
Koide et al., 1999 [28] 52 58 N+, M+, V+ 0.007 0.05
Koide et al., 2001 [24] 60 58 N+, M+, L+, V+ 0.0001 0.05
Li et al., 2000 [25] 96 65 dI, N+ – + –
McDonnell et al., 2001 [39] 42* – –
Millikan et al., 2000 [26] 27* N+
Mukherjee et al., 2003 [44] 55 69 N+ 0.062 –
Nagata et al., 2002 [29] 45 93
Ogata et al., 2003 [42] 92 24 – <0.01 0.018 0.057
Rosa et al., 2003 [41] 47 40 – 0.088 0.15
Sato et al., 1999 [32] 134 49–74 N+
Shih et al., 2000 [27] 117 31 – 0.08 0.04 0.046
Shimada H. et al., 2001 [38] 96 pT, N+, M+ <0.001 0.001
Shimada Y. et al., 1999 [33] 116 69 0.023 0.29
Takeuchi et al., 2004 [45] 90 36 – 0.04
Uchida et al., 1998 [35] 109 60 pT, N+, M+ 0.162 0.007 0.198
Wallner et al., 2001 [31] 32 pT, N+, M+
*Histology not specified; + = positive (p-value not available); – = negative (p-value not available); MVD = microvessel 
density; pT = depth of invasion according to TNM staging system; dI = depth of invasion (other than TNM); N+ = lymph
node metastases; M+ = distant metastases; G = histological differentiation (grading) of tumor; V+ = vascular infiltration; 
L+ = lymph vessel infiltration. 
pression and microvessel density (MVD) [24, 27, 28, 30, 34–36,
40, 42–44, 46]. About 67% of authors who looked for clinico-
pathological parameters, reported associations of VEGF-A
expression and tumor stage, spread, or progression [24–26, 28,
31, 32, 34–36, 38, 43, 44]. Most of them found significant corre-
lations with lymph node metastases, many of them also with
tumor invasiveness (e.g. pT-classification) or presence of dis-
tant metastases, and some of them with vascular invasion or
grade of malignancy (table 1). Nevertheless, 6 out of 18 studies
could not establish any association between VEGF-A expres-
sion and those parameters [27, 30, 39, 41, 42, 45]. However,
most of the studies confirm that VEGF-A contributes to the
aggressive characteristics of esophageal squamous cell carci-
noma, and 72% of the authors demonstrated that VEGF-A
expression correlated significantly with patient outcome [24,
25, 27, 28, 33, 35, 36, 38, 40–42, 45, 46]. In conclusion, VEGF-
A expression seems to be associated with local lymph node
status of esophageal SCC and seems to provide prognostic
value. To date it is not finally clear which of VEGF-A’s func-
tions plays the most important role in the development of
local lymph node metastases, but early tumor spread to local
nodes might possibly be interpreted as a secondary effect of
accelerated tumor growth and invasiveness due to tumor an-
giogenesis and VEGF-A expression. 
Serum Levels of VEGF-A
Pro- and anti-angiogenic factors have been detected in biologi-
cal fluids such as blood, urine, cerebro-spinal fluid or pleural
and peritoneal effusions of tumor patients [47–54]. It remains
unclear whether this phenomenon represents an active expres-
sion or just a pathological passive release of molecules by apop-
totic tumor cells or hematological effector cells such as
macrophages or platelets during inflammatory reactions [47, 55,
56]. Raised levels of circulating VEGF-A were reported in var-
ious types of cancer [57–59] and were associated with poor out-
come [54, 57, 60–64]. Shimada et al. analyzed serum VEGF-A
(S-VEGF) concentration in 99 patients with primary and recur-
rent SCC of the esophagus [38]. S-VEGF was significantly ele-
vated in patients with primary SCC and correlated significantly
with tumor size, positive lymph nodes, distant metastases and
patient survival. Multivariate analysis found S-VEGF to be an
independent prognostic marker. McDonnell et al. also detected
elevated S-VEGF levels in 20 SCC and 24 AC patients [39].
However, they did not find a correlation between S-VEGF lev-
els and tumor stage or survival. This might be explained by
smaller patient numbers and the combination of AC and SCC
patients in one  group. The authors speculate that S-VEGF
might be influenced by tumor-associated macrophages.
Table 1. VEGF-A 
expression in human
squamous cell carci-
noma of the esophagus
Macrophages are potent producers of VEGF-A induced by hy-
poxia and transforming growth factor β1 (TGF β1) [51, 65–67].
Furthermore, alterations in S-VEGF levels might be influenced
by changes in platelet numbers, and therefore measurement 
of plasma-VEGF-A (P-VEGF) instead of serum-VEGF-A 
(S-VEGF) might be more specific [68]. Nevertheless, P-VEGF
levels were also found to correlate with platelet counts of EC
patients [69]. Regardless of the source (growing tumor cells,
apoptotic tumor cells, macrophages or platelets), raised levels
of circulating VEGF-A could be detected in EC patients and
high VEGF-A levels may contribute to the growth of mi-
crometastases at distant sites [70]. However, the prognostic
value of circulating VEGF-A levels remains largely undefined.
VEGF-C and -D Expression in Esophageal Carcinoma
A special feature of EC is its early lymphatic spread into local
lymph nodes. The following studies examined VEGF-C and
VEGF-D expression in EC and their contribution to lymphatic
invasion, lymphangiogenesis and early lymph node metastases.
Ishikawa et al. studied 26 cases of esophageal SCC, 26 normal
tissue samples and 11 cases of esophageal dysplasia [71]. All of
the carcinomas and 82% of the dysplastic samples showed
VEGF-C immunoreactivity, while VEGF-D expression was
observed in 65% of SCC and only 18% of the dysplastic speci-
mens. None of the normal esophageal mucosa samples showed
a positive reaction for VEGF-C or -D. The authors conclude
that VEGF-C and -D might play a positive role in early stages
of esophageal carcinogenesis. Noguchi et al. detected VEGF-C
expression in EC cell lines, pre-operative biopsies and surgical
specimens of esophageal SCC [72]. Normal and dysplastic mu-
cosa did not exhibit VEGF-C expression. VEGFR-3 (flt-4) was
mainly expressed on lymphatic endothelium, and the authors
found significant positive correlations between VEGF-C ex-
pression and tumor stage, depth of the tumor, vascular- and
lymphatic invasion, and lymph node metastases [72]. In con-
trast, Kitadai et al. contest the prognostic value of VEGF-C
expression in esophageal SCC [73]. They could not find any
correlation between VEGF-C immunoreactivity and clinico-
pathological parameters despite histological differentiation. In
Barrett’s disease, Auvinen et al. identified stepwise increasing
VEGF-C expression during progression from Barrett’s epithe-
lium to dysplasia and to Barrett’s carcinoma [18]. VEGFR-3
(flt-4) expression on lymphatic vessels was also up-regulated
during development of esophageal AC and lymphatic vessels
were found to actively penetrate the tumor stroma. Moreover,
VEGF-C and VEGFR-3 (flt-4) expression was identified in
metastatic lymph nodes [18]. In conclusion, VEGF-C and
VEGF-D appear to be expressed in esophageal SCC, AC and
dysplastic epithelium, while normal esophageal epithelium
seems to lack VEGF-C and VEGF-D immunoreactivity.
VEGF-C expression might be associated with more aggressive
disease and VEGF-C seems to be involved in lymphatic tumor
invasion and lymphangiogenesis in esophageal carcinoma. This
mechanism would provide another explanation for the early
onset of lymphatic spread in esophageal carcinomas, a phe-
nomenon which predicts poor outcome. However, prognostic
value of VEGF-C and -D expression in esophageal carcinoma
remains to be evaluated.
VEGF Expression and Treatment Response
Various reports on pre-operative chemo-radiotherapy (CRT)
have indicated advantages for managing esophageal carcino-
ma [74–77]. 3-year survival rates of more than 50% can be ex-
pected in EC patients in whom pre-operative CRT led to a
complete tumor response, which is reported in 20–30% of
cases [78, 79]. On the other hand, peri-operative morbidity
and mortality are increased by CRT. Therefore identification
of factors that could predict a response to CRT is required.
Besides p53, Ki-67, and EGF-R expression [80–82], tissue oxy-
genation has been demonstrated to be very important for de-
termining sensitivity to CRT [83, 84]. Only a well oxygenated
cell is fully radiosensitive [85]. Microcirculation and vessel
permeability are important factors for delivery of oxygen, an-
ticancer drugs and radiosensitizers to cancer cells. Thereby the
predictive value of high microvessel density could be ex-
plained. VEGF-A is known to induce vascular growth and
permeability. Consequently, VEGF-A levels in EC may be
critical for CRT response. However, VEGF-A expression and
microvessel sprouting are also responsible for tumor nutrition,
growth, local invasion and metastatic spread. Therefore, con-
flicting results for the prognostic value of VEGF-A and MVD
during CRT could be expected. Hironaka et al. analyzed pre-
treatment biopsy specimens from 73 SCC patients before de-
finitive CRT (5-FU, cisplatin, 60 Gy) [37]. VEGF-A expres-
sion was reported in 49% of the patients but did not correlate
with clinicopathological parameters. In contrast to former
studies [27, 86, 87], high MVD was a significant positive and
independent prognostic variable for survival. This appears
plausible since the authors counted microvessels with visible
lumens only and conclude that lumen-MVD rather than total
MVD should be a marker of the oxygenation status of the
tumor. On the other hand, high vascular density does not nec-
essarily indicate high blood flow, tissue oxygenation or drug
delivery. A non-functional structure of the immature tumor
vasculature may result in an impaired blood flow [88], and the
interstitial fluid pressure may rise as a consequence of increas-
ing vascular surface and permeability [89]. These two mecha-
nisms may result in reduced drug delivery and tissue oxygena-
tion and finally resistance to CRT. Correspondingly, Imdahl
et al. suggest that esophageal tumors (SCC and AC) with low
VEGF-A expression respond better to CRT [40, 89]. Weak
VEGF immunoreactivity in pre-treatment biopsies was associ-
ated with complete tumor response after neoadjuvant CRT 
(5-FU, cisplatin, 36 Gy) and low VEGF-A expression led to
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better long-term survival after CRT and surgery. MVD
showed a weak correlation with VEGF-A expression and
tumor response. Comparable results were found in two recent
studies by Shimada et al., where high amounts of pretreatment 
S-VEGF were associated with tumor progression, poor re-
sponse to CRT (5-FU, cisplatin, 40 Gy) and poor survival in
patients with SCC of the esophagus [38, 90]. VEGF-A expres-
sion was significantly higher in non-responders than in indi-
viduals responding to CRT. No alteration of S-VEGF levels by
neo-adjuvant CRT treatment (5-FU, cisplatin, 40 Gy) was de-
tected in the study by McDonnell et al. [39]. These authors
quantified S-VEGF levels at various days before, during, and
after CRT and surgery in SCC and AC patients. S-VEGF de-
creased below pretreatment levels 3 months after surgery re-
flecting the reduction of tumor mass. Nevertheless, no correla-
tion between S-VEGF levels during CRT and tumor response
to CRT was found. The authors conclude that there must be
an additional source of S-VEGF which is not affected by CRT
in those patients (e.g. macrophages). In conclusion, VEGF-A
expression and vascularization are critical for growth and
spread of EC, but also for the delivery of oxygen, drugs and
radio-sensitizers. How treatment response to CRT is influ-
enced by VEGF-A, vascular density, -permeability, and inter-
stitial fluid pressure in EC remains controversial.
Anti-VEGF Treatment
Several studies were undertaken to show efficacy of anti-
VEGF treatment in tumor models. However, until now only
few authors studied options to interfere with VEGF expres-
sion in experimental esophageal carcinoma. Regarding acid-
induced esophageal ulcers, Baatar et al. enhanced angiogene-
sis and accelerated ulcer healing in rats by local injection of
plasmid cDNA encoding the recombinant human VEGF165
isoform [17]. In contrast Gu et al. reduced VEGF165 expres-
sion in an esophageal SCC cell line (EC109) by transfection of
VEGF165 antisense-RNA [91]. When transplanted into nude
mice, the tumorigenic and angiogenic capability of the tumor
cells was significantly reduced. Another group demonstrated
that the anti-tumor effects of VEGF165 antisense could be im-
proved by placing the antisense construct under the control of
a hypoxia response element (HRE). HRE then drives expres-
sion of the VEGF165 antisense construct in hypoxic areas of
the tumor where VEGF expression is maximal [92]. Regard-
ing antiangiogenic tumor therapy in general, there are many
promising new drugs tested in clinical trials worldwide (www.
cancer.gov/clinicaltrials/developments/anti-angio-table). Some
of them specifically inhibit the VEGF pathway (table 2).
However, until now no published clinical data exist for selec-
tive interference with VEGF signaling in EC patients. 
Conclusion
There is solid evidence that VEGF-A contributes to the ag-
gressive characteristics of esophageal SCC and correlates with
positive lymph nodes and patient’s outcome. Many studies
have shown a prognostic value for VEGF-A assessment in
esophageal SCC and raised levels of circulating serum-VEGF
have been found in many patients. In Barrett’s mucosa angio-
genic properties are acquired at early stages, particularly in
precancerous lesions. However, VEGF-A expression patterns
in AC fail to give prognostic information. Tumor vasculariza-
tion and VEGF expression play a crucial role in delivery of
oxygen, chemotherapeutical drugs and radiosensitizers to the
tumor cells. Nevertheless, in EC patients it remains controver-
sial how treatment response to chemo-radiotherapy is influ-
enced by pre-treatment VEGF-A expression, vascular density,
-permeability and interstitial fluid pressure. VEGF-C expres-
sion appears to be associated with lymphatic tumor invasion,
lymphangiogenesis, and advanced disease in esophageal SCC
and Barrett’s carcinoma. To date only experimental data re-
garding anti-VEGF therapy in esophageal carcinoma exist. It
remains to be seen whether these treatment strategies will
gain clinical relevance.
Table 2. Drugs inhibiting VEGF signaling
Drug Class Function
Angiozyme (Ribozyme) anti flt-1 ribozyme targets VEGFR-1 expression 
Bevacizumab/Avastin (Genentech) recombinant humanized anti-VEGF neutralizing antibody against VEGF
antibody
IMC 1C11 (ImClone) recombinant humanized receptor antibody blocking antibody against VEGFR-2
Rapamycin (Wyeth) mTor inhibitor inhibits VEGF signaling pathway in target cell
SU 5416/Semaxanib (Sugen) selektive RTK inhibitor inhibits tyrosine kinase activity of VEGFR-2
SU 6668 (Sugen) multitarget RTK inhibitior inhibits tyrosine kinase activity of VEGFR-2, FGFR-1, PDGFRb
SU 11248 (Sugen) multitarget RTK inhibitior inhibits tyrosine kinase activity of VEGFR-2, flt-3, PDGFRb
ZD 4190 (AstraZeneca) selektive RTK inhibitor inhibits tyrosine kinase activity of VEGFR-2
ZD 6474 (AstraZeneca) multitarget RTK inhibitior inhibits tyrosine kinase activity of VEGFR-2, EGFR
ZK 222584/ PTK787 (Novartis) selektive RTK inhibitor inhibits tyrosine kinase activity of VEGFR-1 and VEGFR-2
RTK = Receptor tyrosine kinase.
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